New hope for myelofibrosis patients who failed JAK inhibitors

NCT ID NCT07443306

Recruiting now Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Mar 05, 2026 · Last updated Apr 24, 2026 · Updated 4 times

Summary

This study tests a new oral drug, Flonoltinib maleate, in about 64 adults with intermediate- or high-risk myelofibrosis whose disease got worse or who could not tolerate JAK inhibitor therapy. The main goal is to see if the drug can shrink the spleen by at least 35%. Participants take the drug once daily on an empty stomach until they meet withdrawal criteria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITING

Tianjin, Tianjin Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
West China Hospital Sichuan University
RECRUITING

Chengdu, Sichuan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MF